Medical news
-
Report on the Annual Global Survey 2015 now available
The Report on the Annual Global Survey 2015 is now available in print and online at www.wfh.org/globalsurvey. The report...
-
A new and exciting aspect of the coagulation system
All the players in the coagulation system are known—or are they? Thrombin is a key enzyme in the system that controls clot formation; too much...
-
New inhibitor therapies have the potential to change hemophilia treatment
Considering that the treatment of hemophilia with inhibitors remains problematic, and that inhibitors may be an important consideration for new approaches such as gene therapy,...
-
WFH Vice President, Medical: The future of hemophilia treatment is very promising
Hemophilia treatment has entered an exciting era, with new products making diagnosis and treatment available for a far larger population than ever before, said WHF...
-
Gene therapy delivery options explored
This year’s WFH World Congress featured a session where scientists involved in gene therapy approaches to hemophilia provided updates on developments in the delivery of...
-
WFH Endorses NHF-McMaster Guideline on Care Models for Hemophilia Management
A number of national and international guidance documents, including the WFH Guidelines for the Management of Hemophilia, have supported integrated care as the optimal model...
-
SIPPET study results published in New England Journal of Medicine
May, 2016 – The results of the SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) study were published today in the New England Journal of...
-
EMA committee completes review of Kogenate Bayer/Helixate NexGen studies
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has completed a review of data examining the risk of inhibitors associated with...
-
vCJD case reported in patient with a different genotype
The first case of variant Creutzfeldt-Jakob disease (vCJD) in a patient that is genetically different from all previous confirmed cases has been been reported in...
-
EMA investigating rare adverse events associated with hepatitis C treatment
The European Medicines Agency (EMA) has started a review of medicines known as direct-acting antivirals used for treating chronic hepatitis C infection. There have been...
